1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
France Head and Neck
Cancer Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1.
By Type (Diagnostic Methods, Treatment Type)
5.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
5.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
5.2.2. By Disease
Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer,
Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
5.2.3. By Route
of Administration (Injectable, Oral)
5.2.4. By Therapeutic
Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
5.2.5. By End
User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.6. By
Region
5.2.7. By Company
(2022)
5.3. Market Map
5.3.1. By Type
5.3.2. By Disease Indication
5.3.3. By Route of Administration
5.3.4. By Therapeutic Class
5.3.5. By End User
5.3.6. By Region
6.
Northern France Head
and Neck Cancer Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1.
By Type (Diagnostic Methods, Treatment Type)
6.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
6.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
6.2.2.
By Disease Indication (Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer)
6.2.3.
By Route of Administration (Injectable, Oral)
6.2.4.
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors,
Microtubule Inhibitors)
6.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
7. Southern France Head and Neck Cancer Market Outlook
7.1.
Market Size &
Forecast
7.1.1. By Value
7.2.
Market Share &
Forecast
7.2.1.
By Type (Diagnostic Methods, Treatment Type)
7.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
7.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
7.2.2.
By Disease Indication (Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer)
7.2.3.
By Route of Administration (Injectable, Oral)
7.2.4.
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors,
Microtubule Inhibitors)
7.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
8. Western France Head and Neck Cancer Market Outlook
8.1.
Market Size &
Forecast
8.1.1. By Value
8.2.
Market Share &
Forecast
8.2.1.
By Type (Diagnostic Methods, Treatment Type)
8.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
8.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
8.2.2.
By Disease Indication (Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer)
8.2.3.
By Route of Administration (Injectable, Oral)
8.2.4.
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors,
Microtubule Inhibitors)
8.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
9. Central France Head and Neck Cancer Market Outlook
9.1.
Market Size &
Forecast
9.1.1. By Value
9.2.
Market Share &
Forecast
9.2.1.
By Type (Diagnostic Methods, Treatment Type)
9.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
9.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
9.2.2.
By Disease Indication (Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer)
9.2.3.
By Route of Administration (Injectable, Oral)
9.2.4.
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors,
Microtubule Inhibitors)
9.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
10. Eastern France Head and Neck Cancer Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Type (Diagnostic Methods, Treatment Type)
10.2.1.1.
By Diagnostic Methods (Biopsy, Imaging, Endoscopy,
Others)
10.2.1.2.
By Treatment Type (Surgery, Radiation Therapy,
Chemotherapy, Immunotherapy, Targeted Therapy)
10.2.2.
By Disease Indication (Lip and Oral Cavity Cancer,
Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer)
10.2.3.
By Route of Administration (Injectable, Oral)
10.2.4.
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors,
Microtubule Inhibitors)
10.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
11. Southwestern France Head and Neck Cancer Market Outlook
11.1.
Market Size &
Forecast
11.1.1. By Value
11.2.
Market Share &
Forecast
11.2.1. By Type
(Diagnostic Methods, Treatment Type)
11.2.1.1. By Diagnostic
Methods (Biopsy, Imaging, Endoscopy, Others)
11.2.1.2. By Treatment
Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted
Therapy)
11.2.2. By Disease
Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer,
Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
11.2.3. By Route
of Administration (Injectable, Oral)
11.2.4. By Therapeutic
Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
11.2.5. By End
User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends & Developments
13.1.
Recent Developments
13.2.
Mergers &
Acquisitions
13.3.
Product Launches
14. Policy & Regulatory Landscape
15.
Porter’s Five Forces Analysis
15.1.
Competition in the
Industry
15.2.
Potential of New
Entrants
15.3.
Power of Suppliers
15.4.
Power of Customers
15.5.
Threat of Substitute
Products
16. France Economic Profile
17. Competitive Landscape
17.1.
Business Overview
17.2.
Product Offerings
17.3.
Recent Developments
17.4.
Financials (As Reported)
17.5.
Key Personnel
17.6.
SWOT Analysis
17.6.1.
Eli Lilly and Company
17.6.2.
Bristol Myers Squibb France
17.6.3.
Sanofi SA/France
17.6.4.
Merck & Co., Inc.
17.6.5.
Pfizer Inc.
17.6.6.
AbbVie SAS
17.6.7.
Bayer AG
17.6.8.
Sun Pharmaceuticals France
17.6.9.
Teva Pharmaceutical Industries Limited
17.6.10.
AstraZeneca
France
Strategic Recommendations